Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

4250 - Phase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Erika Martinelli

Citation

Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246

Authors

E. Martinelli1, T. Troiani1, C. Cardone1, D. Ciardiello1, N. Zanaletti1, C. Borrelli1, M. Terminiello1, A. Avallone2, A. Falcone3, E. Maiello4, R. Bordonaro5, D. Santini6, C. Garufi7, F. Pietrantonio8, C. Pinto9, G. Santabarbara10, N. Normanno11, F. Ciardiello1

Author affiliations

  • 1 Medical Oncology, Università degli Studi della Campania Luigi Vanvitelli, 80131 - Napoli/IT
  • 2 Medical Oncology, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, 80131 - Napoli/IT
  • 3 Medical Oncology, Azienda Ospedaliera Universitaria S.Chiara, 56100 - Pisa/IT
  • 4 Medical Oncology, Ospedale Casa Sollievo della Sofferenza, 71013 - San Giovanni Rotondo/IT
  • 5 Medical Oncology, Azienda Ospedaliera ARNAS Garibaldi, 95100 - Catania/IT
  • 6 Oncology, Policlinico Universitario Campus Bio-Medico, 00128 - Rome/IT
  • 7 Onco-hematology, Ospedale Di Pescara, Pescara/IT
  • 8 Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan/IT
  • 9 Clinical Canncer Centre, Medical Oncology Unitr, Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, 42100 - Reggio Emilia/IT
  • 10 Oncolematologia Dept., Azienda Ospedaliera S. Giuseppe Moscati, 83100 - Avellino/IT
  • 11 Cell Biology And Biotherapy Unit, National Cancer Institute ‘Fondazione Giovanni Pascale’, 80100 - Napoli/IT

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4250

Background

The immune system plays a pivotal role in modulating response to monoclonal antibodies therapy in cancer. Novel immune-checkpoint inhibitors have demonstrated potent efficacy alone and in combinations with cytotoxic agents in several cancers. In this regard, avelumab in combination with cetuximab might be a relevant re-challenge strategy in RAS wild type (WT) metastatic colorectal cancer (mCRC) patients treated in first line with chemotherapy (CT) in combination with anti-epidermal growth factor receptor (EGFR) drugs and who achieved a complete or partial response.

Trial design

CAVE Colon is a single arm, multi-center phase II study designed to evaluate the efficacy of avelumab and cetuximab in pre-treated RAS WT mCRC patients. Eligible patients: pathologically confirmed KRAS (exon 2, 3 and 4) and NRAS (exon 2, 3 and 4) WT mCRC treated with a first line CT in combination with an anti-EGFR agent with a major response achieved (complete or partial), who have progressed to a second line therapy, and received no prior immunotherapy. Primary endpoint is overall survival; secondary endpoints are overall response rate according to RECIST 1.1, progression free survival and safety profile. This study seeks to demonstrate a median OS of 11 months by the experimental combination for comparison with historical median OS 8.0 with standard third line treatments, which correspond to an improvement of OS at 6 months from 40% to 57%. With 80% power and 1-sided 5% level test, it was estimated that it would be needed to enrol 66 patients. Considering a potential dropout of approximately 15% of patients, a total of 75 patients will be recruited. The accrual period, started in August 2018, will be 18 months and the total duration of the study will be 36 months. As per April 22nd 2019, thirty-five patients have been enrolled and started the treatment with avelumab 10 mg/kg q14 as a 1-hour i.v. infusion and cetuximab at 400 mg/m2 over 2-hour and subsequently 250 mg/m2 q7 as 1-hour i.v. infusion until disease progression or unacceptable toxicity.

Clinical trial identification

2017-004392-32.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

This study is partially supported by Merck KgA, Darmstadt, Germany.

Disclosure

E. Martinelli: Advisory / Consultancy: Amgen, Bayer, Merck, Roche, Sanofi, Servier. T. Troiani: Advisory / Consultancy: Amgen, Bayer, Merck, Novartis, Roche. F. Ciardiello: Advisory / Consultancy: Merck Kga, Bayer, Amgen, Rocher, Servier, Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.